Alexza Pharma (ALXA) trading halted with news pending
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Alexza Pharma (ALXA) Resumes, Shares Move Lower
December 21, 2012 4:15 PM ESTAlexza Pharma (NASDAQ: ALXA) shares resume trading, shares are down 6 percent late Friday.... More
Alexza Pharma (ALXA) to resume trading at 4:15pm ET
December 21, 2012 3:31 PM ESTAlexza Pharma (NASDAQ: ALXA) to resume trading at 4:15pm EST.... More
FDA Approves Alexza's (ALXA) Adusave
December 21, 2012 3:28 PM ESTAlexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the U.S. Food and Drug Administration (FDA) approved ADASUVE® (loxapine) Inhalation Powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. ADASUVE combines Alexza's proprietary Staccato® delivery system with the antipsychotic drug, loxapine. The Staccato system is a hand-held inhaler that delivers a drug aerosol to the deep lung that results in rapid systemic delivery and absorption of a drug. See below for Important Safety Information about ADASUVE, including Boxed Warnings.
... More
